BIOSTATE human coagulation factor VIII 250IU / von Willebrand Factor 600IU powder for injection vial with diluent vial Australia - englanti - Department of Health (Therapeutic Goods Administration)

biostate human coagulation factor viii 250iu / von willebrand factor 600iu powder for injection vial with diluent vial

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

ARISTOCORT 0.02% OINTMENT triamcinolone acetonide 0.2mg/g tube Australia - englanti - Department of Health (Therapeutic Goods Administration)

aristocort 0.02% ointment triamcinolone acetonide 0.2mg/g tube

aspen pharmacare australia pty ltd - triamcinolone acetonide, quantity: 0.2 mg/g - ointment - excipient ingredients: white soft paraffin - indications as at 22 october 1998: in the treatment of the following dermatoses: atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, exzematised psoriasis, neurodermatitis.

ARISTOCORT 0.02% CREAM triamcinolone acetonide 0.2mg/g tube Australia - englanti - Department of Health (Therapeutic Goods Administration)

aristocort 0.02% cream triamcinolone acetonide 0.2mg/g tube

aspen pharmacare australia pty ltd - triamcinolone acetonide, quantity: 0.2 mg/g - cream - excipient ingredients: emulsifying wax; benzyl alcohol; lactic acid; purified water; glycerol; sorbitol solution (70 per cent) (non-crystallising); isopropyl palmitate - indications as at 22 october 1998: in the treatment of the following dermatoses: atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, exzematised psoriasis, neurodermatitis.

ZATAMIL 0.1% OINTMENT mometasone furoate 0.1% w/w (1 mg/g) ointment tube Australia - englanti - Department of Health (Therapeutic Goods Administration)

zatamil 0.1% ointment mometasone furoate 0.1% w/w (1 mg/g) ointment tube

ego pharmaceuticals pty ltd - mometasone furoate, quantity: 1 mg/g - ointment - excipient ingredients: hexylene glycol; citric acid; light liquid paraffin; purified water; white soft paraffin; polyethylene; colloidal anhydrous silica; cetostearyl alcohol - for the short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as psoriasis and atopic dermatitis.

ZATAMIL 0.1% HYDROGEL mometasone furoate 0.1% w/w (1 mg/g) gel tube Australia - englanti - Department of Health (Therapeutic Goods Administration)

zatamil 0.1% hydrogel mometasone furoate 0.1% w/w (1 mg/g) gel tube

ego pharmaceuticals pty ltd - mometasone furoate, quantity: 1 mg/g - gel - excipient ingredients: hexylene glycol; citric acid; hypromellose; purified water - for the short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as psoriasis and atopic dermatitis.

ZATAMIL 0.1% LOTION mometasone furoate 0.1% w/w (1 mg/g) lotion bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

zatamil 0.1% lotion mometasone furoate 0.1% w/w (1 mg/g) lotion bottle

ego pharmaceuticals pty ltd - mometasone furoate, quantity: 1 mg/g - lotion - excipient ingredients: industrial methylated spirit; citric acid; propylene glycol; hypromellose; purified water - for the short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as psoriasis and atopic dermatitis.,zatamil lotion is suitable for use in scalp psoriaris and application to other areas of the body.

TRICORTONE 0.02% OINTMENT triamcinolone acetonide 0.2mg/g tube Australia - englanti - Department of Health (Therapeutic Goods Administration)

tricortone 0.02% ointment triamcinolone acetonide 0.2mg/g tube

aspen pharmacare australia pty ltd - triamcinolone acetonide, quantity: 0.2 mg/g - ointment - excipient ingredients: white soft paraffin - indications as at 22 october 1998: in the treatment of the following dermatoses: atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, exzematised psoriasis, neurodermatitis.

TRICORTONE 0.02% CREAM triamcinolone acetonide 0.2mg/g tube Australia - englanti - Department of Health (Therapeutic Goods Administration)

tricortone 0.02% cream triamcinolone acetonide 0.2mg/g tube

aspen pharmacare australia pty ltd - triamcinolone acetonide, quantity: 0.2 mg/g - cream - excipient ingredients: emulsifying wax; lactic acid; purified water; isopropyl palmitate; glycerol; benzyl alcohol; sorbitol solution (70 per cent) (non-crystallising) - indications as at 22 october 1998: in the treatment of the following dermatoses: atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, exzematised psoriasis, neurodermatitis.

ARIXTRA fondaparinux sodium 2.5mg/0.5mL solution for injection syringe Australia - englanti - Department of Health (Therapeutic Goods Administration)

arixtra fondaparinux sodium 2.5mg/0.5ml solution for injection syringe

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery.,arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.,arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe).,arixtra is indicated for the treatment of unstable angina or non-st segment elevation myocardial infarction (ua/nstemi) for whom urgent (<120 min) invasive management (pci) is not indicated.,arixtra is indicated for the treatment of st segment elevation myocardial infarction (stemi) in patients who are managed without any form of initial reperfusion therapy.

ZATAMIL 0.1% LOTION mometasone furoate 0.1% w/w (1 mg/g) lotion bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

zatamil 0.1% lotion mometasone furoate 0.1% w/w (1 mg/g) lotion bottle

ego pharmaceuticals pty ltd - mometasone furoate, quantity: 1 mg/g - lotion - excipient ingredients: ethanol; citric acid; propylene glycol; hypromellose; purified water - for the short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as psoriasis and atopic dermatitis.,zatamil lotion is suitable for use in scalp psoriaris and application to other areas of the body.